Germline Variants in Highly Selected Patients with Prostate Cancer

Samantha Greenberg; Jonathan Tward; Brock O'Neil

doi:10.1001/jamaoncol.2019.2115

Germline Variants in Highly Selected Patients with Prostate Cancer

Samantha Greenberg, Jonathan Tward, Brock O'Neil

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1368-1369
Number of pages	2
Journal	JAMA Oncology
Volume	5
Issue number	9
DOIs	https://doi.org/10.1001/jamaoncol.2019.2115
State	Published - Sep 2019
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2019.2115

Cite this

@article{8e5ffbb4e3454027b28309c9dc6bbb97,

title = "Germline Variants in Highly Selected Patients with Prostate Cancer",

author = "Samantha Greenberg and Jonathan Tward and Brock O'Neil",

note = "Funding Information: Conflict of Interest Disclosures: Ms Greenberg reported personal fees from Tempus outside the submitted work. Dr Tward reported personal fees from Myriad and grants from Myriad during the conduct of the study; personal fees from Blue Earth Diagnostics, Merck, and Janssen outside the submitted work. Dr O{\textquoteright}Neil reported grants from the National Cancer Institute during the conduct of the study. 11 07 2019 12 09 2019 September 2019 5 9 1368 1369 27 02 2019 04 03 2019 Copyright 2019 American Medical Association. All Rights Reserved. cle190032.pdf ",

year = "2019",

month = sep,

doi = "10.1001/jamaoncol.2019.2115",

language = "English (US)",

volume = "5",

pages = "1368--1369",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Germline Variants in Highly Selected Patients with Prostate Cancer

AU - Greenberg, Samantha

AU - Tward, Jonathan

AU - O'Neil, Brock

N1 - Funding Information: Conflict of Interest Disclosures: Ms Greenberg reported personal fees from Tempus outside the submitted work. Dr Tward reported personal fees from Myriad and grants from Myriad during the conduct of the study; personal fees from Blue Earth Diagnostics, Merck, and Janssen outside the submitted work. Dr O’Neil reported grants from the National Cancer Institute during the conduct of the study. 11 07 2019 12 09 2019 September 2019 5 9 1368 1369 27 02 2019 04 03 2019 Copyright 2019 American Medical Association. All Rights Reserved. cle190032.pdf

PY - 2019/9

Y1 - 2019/9

UR - http://www.scopus.com/inward/record.url?scp=85068902910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068902910&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.2115

DO - 10.1001/jamaoncol.2019.2115

M3 - Letter

C2 - 31294753

AN - SCOPUS:85068902910

SN - 2374-2437

VL - 5

SP - 1368

EP - 1369

JO - JAMA Oncology

JF - JAMA Oncology

IS - 9

ER -

Germline Variants in Highly Selected Patients with Prostate Cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this